Dr. Tony Ho is a distinguished leader in the biotech industry, currently serving as Chief Scientific Officer at Pivotal Biosciences. Tony was Executive Vice President, and Head of Research and Development at CRISPR Therapeutics. Over four years, he developed a world-class R&D engine and a robust pipeline of over 10 product candidates, including the first approved CRISPR-based therapy, Casgevy, three allogeneic CAR-T therapies, and the first CRISPR-edited pancreatic islet progenitor cells, VCTX210.

Previously, Tony was SVP and Head of Oncology Integration and Innovation at AstraZeneca, overseeing the development and commercialization of Lynparza and Imfinizi. He led 10 Phase 3 trials to positive outcomes and successfully repositioned a failed NK3 antagonist for PCOS. Before AstraZeneca, he headed Neurology and Ophthalmology at Merck, leading the development of Zioptan and multiple Phase 3 programs. Tony co-founded Neuronyx, developing stem cells for various conditions. He holds a B.S. in Electrical Engineering from UCLA and an M.D. from Johns Hopkins, where he was an Assistant Professor specializing in neuropathy. He has published over 80 papers and is currently an Adjunct Associate Professor of Neurology at the University of Pennsylvania and an Assistant Professor of Neurology at Johns Hopkins University.